%PDF-1.3
%
2 0 obj
<>
endobj
22 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
24 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
23 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
27 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
26 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
1 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
15 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
20 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
6 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
25 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
4 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
8 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
14 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
18 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
19 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
16 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
11 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
10 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
28 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
21 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
17 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
29 0 obj
<>stream
2012-02-01T07:14:10+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2012-04-06T01:42:37-07:00
Acrobat Distiller 8.1.0 (Windows)
application/pdf
untitled
uuid:52e05629-4dad-4acf-9a1e-7b61756017d3
uuid:05ef40ed-f488-42b3-8843-ee4363476b5f
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 Bid]1D. pa
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 Bid]D. qdj
endstream
endobj
34 0 obj
<>stream
x+ |
endstream
endobj
35 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
36 0 obj
<>stream
x+ |
endstream
endobj
37 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
38 0 obj
<>stream
x+ |
endstream
endobj
39 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
40 0 obj
<>stream
x+ |
endstream
endobj
41 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
42 0 obj
<>stream
x+ |
endstream
endobj
43 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
44 0 obj
<>stream
x+ |
endstream
endobj
45 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
46 0 obj
<>stream
x+ |
endstream
endobj
47 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
48 0 obj
<>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 57 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
58 0 obj
<>/ProcSet[/PDF/Text]/Font<>>>
endobj
50 0 obj
<>stream
/GS1 gs
BT
/F6 1 Tf
8.9663 0 0 8.9663 62.022 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(pharmacy.)-223.6(Prior)-224(low)-222.9(use)-223.9(has)-225.5(been)-222.6(documented)-225.6(for)-218.9(women)-226.6(by)]TJ
0 -1.2203 TD
[(BRFSS)-362.7(and)-366.3(in)-361(the)-364.2(REACH)-362.9(Registry.)-363.3(BRFSS)-362.7(surveyed)-365.4(a)-366.2(rep-)]TJ
0 -1.2266 TD
[(resentative)-477.7(sample)-471.1(in)-468.5(1999)-472.3(of)-471.1(noninstitutionalized)-479(persons)]TJ
0 -1.2203 TD
(aged)Tj
/F9 1 Tf
2.7568 0 TD
()Tj
/F6 1 Tf
.7145 0 TD
[(40)-466.9(years.)]TJ
6.7246 0 0 5.9768 129.3165 696.8691 Tm
(15)Tj
8.9663 0 0 8.9663 140.2015 692.9006 Tm
[(The)-467.9(study,)-462.4(using)-469.3(the)-459(REACH)-470.4(Registry,)]TJ
-8.7193 -1.2203 TD
[(examined)-211.3(data)-211.2(collected)-214(between)-218.3(the)-212.4(years)-208.2(2003)-213(and)-208.2(2006)-206.7(and)]TJ
0 -1.2266 TD
[(focused)-311.6(on)-316(criteria)-311.1(for)-313.8(secondary)-311.5(prevention)-319.6(only.)]TJ
6.7246 0 0 5.9768 260.3338 674.9856 Tm
(16)Tj
8.9663 0 0 8.9663 269.8582 670.9604 Tm
[(Our)-314.9(ob-)]TJ
-23.1798 -1.2203 TD
[(jectives)-497(were)-501.6(to)-496.4(determine)-495.2(the)-496.9(prevalence)-501.4(of)-496.4(self-reported)]TJ
T*
[(aspirin)-367.4(use)-363(in)-367.3(women)-365.7(for)-364.3(both)-365.1(primary)-368.2(and)-366.3(secondary)-368.4(pre-)]TJ
0 -1.2266 TD
[(vention)-336.7(of)-338.4(CVD)-333.2(events,)-337.4(the)-338.9(predictors)-335.5(of)-338.4(aspirin)-335.8(use)-337.7(among)]TJ
0 -1.2203 TD
[(women)-340.4(primarily)]TJ
/F9 1 Tf
8.2767 0 TD
(>)Tj
/F6 1 Tf
.7145 0 TD
[(age)-345.3(65,)-337.1(and)-341(changes)-346.3(in)-342(aspirin)-342.1(use)-344(over)]TJ
-8.9912 -1.2203 TD
[(time)-298.6(from)-292.4(2004)-295.2(to)-294.1(2009)-295.2(after)-298.2(the)-294.6(AHA)-300(guidelines)-295.8(for)-294.8(women)]TJ
T*
[(were)-280.3(released)-286(in)-278.8(2007.)]TJ
6.7246 0 0 5.9768 148.9322 609.2219 Tm
(2)Tj
/F4 1 Tf
8.9663 0 0 8.9663 62.022 577.814 Tm
[(Materials)-332.7(and)-338.2(Methods)]TJ
/F10 1 Tf
0 -1.8336 TD
[(Setting)-337.7(and)-329.4(study)-333.9(design)]TJ
/F6 1 Tf
1.1128 -1.8336 TD
(HeartAware)Tj
/F9 1 Tf
6.7246 0 0 5.9768 120.9259 548.9573 Tm
()Tj
/F6 1 Tf
8.9663 0 0 8.9663 130.9039 544.9321 Tm
[(is)-447.4(a)-442.1(web-based)-450.8(CVD)-447(risk)-446.2(assessment)-454.9(tool)]TJ
-7.6823 -1.2203 TD
[(\(Navigant,)-318.4(Healthcare,)-318.9(Chicago,)-319.5(IL\).)-312(Raw)-315.2(data)-318.6(were)-311.9(cleaned)]TJ
T*
[(and)-227.2(analyzed)-221.4(by)-223.8(researchers)-227.9(at)-221.3(Scott)-229.1(and)-220.9(White)-227.6(\(Temple,)-223.6(TX\).)]TJ
0 -1.2266 TD
[(Data)-228.5(were)-223.4(extracted)-226.7(from)-229.1(127)-219.8(participating)-229.7(healthcare)-230.9(centers)]TJ
0 -1.2203 TD
[(\(academic,)-403.3(community,)-411.6(for-prot,)-407.7(and)-404.2(not-for-prot\))-412.3(in)-405.3(the)]TJ
T*
[(United)-277.2(States)-278.4(that)-275.7(offered)-279.1(the)-275.6(HeartAware)-281.9(program)-278.9(between)]TJ
T*
[(2004)-251(and)-252.5(2009;)-247.6(HeartAware)-256.6(is)-251.4(not)-253.2(currenly)-253.5(available)-254.5(through)]TJ
0 -1.2266 TD
[(any)-197(independent)-198.3(physician)-203.1(practice.)-196.6(Individuals)-195.8(participating)]TJ
0 -1.2203 TD
[(in)-512.8(the)-515.9(survey)-507.9(access)-519.1(the)-509.6(HeartAware)-515.9(survey)-514.3(through)-516(the)]TJ
T*
[(participating)-330.9(organizations)-330.2(website,)-323.9(and)-322(most)-330.9(sites)-322.7(increase)]TJ
0 -1.2266 TD
[(survey)-482.6(participation)-481(by)-476.7(various)-484.1(media)-477.7(advertisements,)-482.5(in-)]TJ
0 -1.2203 TD
[(cluding)-416.9(mail,)-411.7(television,)-414(and)-416.9(radio)-414.2(ads.)-411.4(The)-417.3(online)-414.9(risk)-414.6(as-)]TJ
T*
[(sessment)-258.1(takes)-252.2(approximately)-257.1(710)-251(minutes)-260.4(to)-249.8(complete.)-254.3(The)]TJ
0 -1.2266 TD
[(goal)-244.2(of)-243.5(the)-244(HeartAware)-244(program)-247.3(is)-238.8(to)-243.5(identify)-246.3(people)-249.1(with)-243(or)]TJ
0 -1.2203 TD
[(at)-265.5(risk)-269.2(for)-269.5(CVD)-269.9(who)-267(may)-267.1(not)-272.2(be)-263.6(aware)-266.8(of)-268.8(their)-273.6(personal)-265.4(risk.)]TJ
T*
[(The)-328.8(use)-331.4(of)-332(the)-332.5(risk)-332.4(assessment)-334.8(tool)-332(is)-327.3(voluntary,)-336(and)-328.4(results)]TJ
T*
[(are)-284.6(condential.)]TJ
1.1128 -1.2266 TD
[(The)-328.8(variables)-329.3(collected)-327.8(in)-329.4(the)-326.2(survey)-330.9(include)-330.1(age,)-322.9(gender,)]TJ
-1.1128 -1.2203 TD
[(ethnicity,)-501.8(height,)-498.6(weight,)-496.8(body)-501.5(mass)-492.9(index)-498.8(\(BMI\),)-501(aerobic)]TJ
T*
[(activity)-334.4(level,)-333(information)-334.2(on)-328.6(CVD)-333.2(risk)-332.4(factors)-333.3(\(tobacco)-331.5(use,)]TJ
0 -1.2266 TD
[(diabetes)-429.4(mellitus,)-431.4(hypertension,)-438.4(hyperlipidemia\))-430.4(,)-426.5(forms)-432.8(of)]TJ
0 -1.2203 TD
[(CVD)-244.7(\(i.e.,)-240.3(coronary,)-244.1(cerebral,)-244.8(and)-246.2(peripheral)-247.8(arterial)-241.8(disease\),)]TJ
T*
[(related)-335.8(procedures)-339.1(\(i.e.,)-335.1(angioplasty,)-330.6(coronary)-336(artery)-334.5(bypass)]TJ
0 -1.2266 TD
[(surgery)-537.6([CABG]\),)-538.8(medication)-537.8(use)-540(including)-537.6(daily)-538.8(aspirin,)]TJ
0 -1.2203 TD
[(family)-274.6(history,)-278.8(and)-271.5(whether)-274.9(the)-275.6(subject)-277.3(is)-276.7(under)-273.9(the)-275.6(care)-277.6(of)-275.1(a)]TJ
T*
[(physician.)-218.7(The)-214.9(question)-219.5(ascertaining)-221.3(aspirin)-215.7(use)-211.2(was)-217.4(stated)-219.6(as)]TJ
0 -1.2267 TD
[(follows:)-417.3(Are)-413(you)-413.2(taking)-420.4(any)-412(of)-414.2(the)-414.7(following)-418.1(medications?)]TJ
0 -1.2203 TD
[(Arthritis)-413.8(medications,)-415.5(cholesterol)-415.9(medications,)-415.5(aspirin)-411.7(on)-417.1(a)]TJ
T*
[(regular)-364.2(basis,)-367.1(blood)-364.3(pressure)-366.9(medications,)-371.3(diabetes)-366.1(medica-)]TJ
T*
[(tion,)-259.7(none.)-259(Respondents)-261.3(were)-255(able)-254(to)-256.2(check)-259.2(all)-259.5(responses)-258.5(that)]TJ
0 -1.2266 TD
[(applied)-486.4(to)-483.8(them.)-484.8(De-identied)-489.4(data)-489.4(were)-482.7(provided)-489.2(to)-483.8(the)]TJ
0 -1.2203 TD
[(authors,)-347.5(omitting)-344.9(dates)-339.3(of)-344.7(assessment)-347.4(and)-341(personal)-347.6(identi-)]TJ
T*
[(ers.)-377.9(All)-375.2(study)-377.3(procedures)-383.3(and)-372.6(ethics)-380.9(were)-375.2(approved)-382.4(by)-375.6(the)]TJ
0 -1.2266 TD
[(Institutional)-285.1(Review)-281.8(Board)-280.9(of)-281.5(Scott)-286(and)-284.1(White.)]TJ
/F10 1 Tf
0 -2.4406 TD
(Measures)Tj
/F6 1 Tf
1.1128 -1.8336 TD
[(The)-303.5(dependent)-305.2(measure)-303.7(was)-299.6(aspirin)-304.2(use)-299.7(status.)-304.5(This)-302.1(mea-)]TJ
-1.1128 -1.2266 TD
[(sure)-268.8(was)-261.7(assessed)-273.1(by)-261.8(a)-265.1(single)-262.7(survey)-267.7(question.)-273(Responses)-268.4(for)]TJ
0 -1.2203 TD
[(aspirin)-405.4(use)-407.2(were)-400.5(coded)-406.3(as)-405.5(yes)-397.6(or)-408.1(no.)-401.1(Additionally,)-408.1(the)-402.1(fol-)]TJ
T*
[(lowing)-348.1(self-reported)-349.6(variables)-348.3(were)-343.6(used)-347(in)-348.4(this)-343.8(report:)-350.2(eth-)]TJ
T*
[(nicity,)-517.1(certain)-512.6(forms)-515(of)-509.1(CVD)-510.2(\(acute)-519.5(myocardial)-507(infarction)]TJ
0 -1.2266 TD
[([MI],)-504.3(stroke,)-505.7(bypass)-505.5(surgery,)-502.6(cardiac)-504.3(stent,)-508(cardiac)-498(angio-)]TJ
0 -1.2203 TD
[(plasty,)-348.6(carotid)-344.4(surgery,)-344.5(abdominal)-339.7(aortic)-347.7(aneurysm,)-346.2(angina,)]TJ
T*
[(claudication,)-205.5(renal)-196.7(artery)-201.7(stenosis,)-206.6(cardiac)-194.5(arrest,)-201.5(and)-201.9(diabetes)]TJ
0 -1.2267 TD
[(mellitus\),)-476.2(certain)-474.7(risk)-471.5(factors)-472.4(for)-471.8(CVD)-472.3(\(hypertension,)-483.2(high)]TJ
27.9978 74.5598 TD
[(cholesterol,)-450.4(smoking)-441(status,)-443.6(family)-439(history)-440.2(of)-445.8(CVD,)-437.3(family)]TJ
0 -1.2203 TD
[(history)-193.6(of)-180.3(stroke,)-189.5(and)-189.3(physical)-187.1(activity\),)-186.1(and)-182.9(type)-189.5(of)-186.6(healthcare)]TJ
0 -1.2266 TD
[(provider)-360.5(seen)-352.3(by)-350.3(the)-357.8(respondent.)-354.2(Having)-353(hypertension)-359.6(was)]TJ
0 -1.2203 TD
[(dened)-214.5(as)-209.5(either)-216.5(a)-208.2(systolic)-212.7(blood)-212.5(pressure)-215.2(\(SBP\))]TJ
/F9 1 Tf
20.9478 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
[(140)-169.3(mm)-210.1(Hg)]TJ
-21.6686 -1.2203 TD
[(or)-269(a)-265.1(diastolic)-263.5(blood)-263.1(pressure)-272.1(\(DBP\))]TJ
/F9 1 Tf
15.7061 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
[(90)-163.4(mm)-267(Hg)-263.6(or)-262.7(the)-269.3(use)-261.8(of)]TJ
-16.4269 -1.2266 TD
[(antihypertensive)-468.5(medications.)]TJ
6.7246 0 0 5.9768 432.7936 674.9856 Tm
(17)Tj
8.9663 0 0 8.9663 443.6786 670.9604 Tm
[(All)-457.4(prescription)-467.2(antihyper-)]TJ
-14.568 -1.2203 TD
[(tensives)-320.4(and)-309.4(diabetes)-315.5(medications)-317.8(were)-311.9(recoded)-318.4(into)-313.7(indica-)]TJ
T*
[(tors)-751.4(of)-755.7(hypertensive)-752.5(medication)-752.7(\(yes/no\))-755.5(and)-745.7(diabetes)]TJ
0 -1.2266 TD
[(medication)-297.5(\(yes/no\).)-296.9(High)-289.5(cholesterol)-295.8(was)-293.3(dened)-296.7(as)-291.7(a)-290.4(total)]TJ
0 -1.2203 TD
(cholesterol)Tj
/F9 1 Tf
5.3365 0 TD
(>)Tj
/F6 1 Tf
.7208 0 TD
[(200)-162.9(mg/dL.)]TJ
6.7246 0 0 5.9768 413.5747 631.1053 Tm
(18)Tj
8.9663 0 0 8.9663 424.3463 627.1368 Tm
[(Smoking)-450.9(status)-453.4(was)-451.4(dened)-454.8(as)]TJ
-12.4119 -1.2203 TD
[(never)-295.5(smoked,)-290.1(currently)-291.9(smoking,)-292.2(or)-294.3(past)-287.2(smoking.)-292.2(Physical)]TJ
T*
[(activity)-328.1(was)-324.9(dened)-328.3(as)-323.3(no)-322.3(exercise,)-325.7(12)-327.3(times)-325.2(per)-324.4(week,)-324.9(34)]TJ
0 -1.2266 TD
[(times)-337.9(per)-337.1(week,)-337.6(or)]TJ
/F9 1 Tf
8.8141 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
[(5)-334.6(times)-337.9(per)-330.7(week.)-337.6(Healthcare)-335(provider)]TJ
-9.535 -1.2203 TD
[(was)-400.8(dened)-404.2(as)-399.2(having)-400.7(a)-397.9(primary)-399.8(care)-397.7(provider)-398.4(\(PCP\))-402.2(or)-401.8(a)]TJ
T*
[(cardiologist,)-287(both,)-279.5(or)-281.7(none.)]TJ
/F10 1 Tf
0 -2.447 TD
[(Study)-338.6(sample)]TJ
/F6 1 Tf
1.1128 -1.8336 TD
[(Between)-248.5(the)-237.7(years)-246.1(2004)-238.3(and)-239.9(2009,)-241.2(responses)-245.9(were)-242.4(collected)]TJ
-1.1128 -1.2203 TD
[(from)-393.5(the)-389.5(participating)-387.8(centers)-397(for)-389.6(320,010)-385.7(men)-386.5(and)-391.6(women)]TJ
0 -1.2266 TD
[(who)-336.6(elected)-341.1(to)-332(take)-333.1(the)-338.9(survey)-337.2(\(Fig.)-331.9(1\).)-338(There)-335.7(was)-331.2(a)-334.6(total)-335.5(of)]TJ
0 -1.2203 TD
[(217,987)-240.3(women)-239.2(respondents.)-248(Using)-241.7(the)-237.7(2007)-238.3(AHA)-243(guidelines)]TJ
T*
[(summarized)-320.1(in)-316.7(Table)-313.9(1,)-312.2(women)-315.1(were)-318.3(considered)-320.3(eligible)-313.6(for)]TJ
T*
[(aspirin)-487.5(use)-476.8(for)-484.5(primary)-482(prevention)-484(of)-483.8(CVD)-478.6(\(primary)-482.5(pre-)]TJ
0 -1.2266 TD
[(vention)-216.5(group\))-213.4(if)-212.7(they)-210.5(were)]TJ
/F9 1 Tf
12.2032 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
[(65)-207.7(years)-214.5(of)-205.6(age)-212.5(at)-208.6(the)-212.4(time)-210.1(of)-211.9(the)]TJ
-12.924 -1.2203 TD
[(survey)-400.4(and)-391.6(did)-395.2(not)-392.3(meet)-396.2(criteria)-393.3(for)-396(secondary)-393.7(prevention.)]TJ
T*
[(Meeting)-421.4(criteria)-418.6(for)-414.9(secondary)-419(prevention)-420.8(of)-414.2(CVD)-415.4(through)]TJ
0 -1.2266 TD
[(daily)-330.1(aspirin)-335.8(use)-331.4(\(secondary)-330.9(prevention)-338.6(group\))-333.5(was)-331.2(dened)]TJ
0 -1.2203 TD
[(by)-445.1(a)-435.8(history)-446.6(of)-439.5(any)-443.6(of)-439.5(the)-440(following)-443.4(conditions:)-450(acute)-436.8(MI,)]TJ
T*
[(stroke,)-278.1(abdominal)-282.8(aortic)-271.8(aneurysm,)-283(coronary)-272.8(artery)-277.6(stenting,)]TJ
0 -1.2266 TD
[(bypass)-417(surgery,)-414.1(balloon)-411.9(angioplasty,)-412.8(or)-408.1(carotid)-413.9(endarterec-)]TJ
0 -1.2203 TD
[(tomy.)-343.3(Individuals)-341.2(with)-344.1(diabetes)-340.8(mellitus)-340(or)-344.9(those)-336.6(taking)-344.5(di-)]TJ
T*
[(abetes)-998.2(medications)-994.3(were)-988.5(included)-997(in)-987(the)-996.5(secondary)]TJ
T*
[(prevention)-762.2(category)-751.2(following)-753.2(the)-756.2(National)-752.5(Cholesterol)]TJ
0 -1.2266 TD
[(Education)-446.3(Program-Adult)-447.2(Treatment)-441.2(Panel)-444(III)-442.6(\(NCEP-ATP)]TJ
0 -1.2203 TD
[(III\))-285(guidelines)-283.1(and)-284.1(the)-282(2007)-276.3(AHA)-281(guidelines.)]TJ
6.7246 0 0 5.9768 489.7133 351.666 Tm
(2,18)Tj
8.9663 0 0 8.9663 323.0361 336.7558 Tm
[(Afrmative)-215.9(responses)-220.6(for)-212.6(angina,)-219(claudication,)-218.1(renal)-215.7(artery)]TJ
-1.1128 -1.2266 TD
[(stenosis,)-307.8(and)-303.1(cardiac)-302(arrest)-306.1(were)-305.6(collected)-302.5(as)-304.3(part)-299.2(of)-306.7(the)-300.9(sur-)]TJ
0 -1.2203 TD
[(vey)-378.1(but)-379.3(were)-381.5(excluded)-378.9(as)-380.2(criteria)-374.4(for)-383.3(secondary)-381(prevention)]TJ
T*
[(because)-277.6(of)-268.8(the)-275.6(potential)-274.2(for)-269.5(misreporting)-278.9(or)-269(faulty)-275.3(responses.)]TJ
0 -1.2266 TD
[(When)-359.8(these)-365.4(variables)-360.9(were)-356.2(included)-358.4(\(all)-361.1(together)-359.8(and)-360(sepa-)]TJ
0 -1.2203 TD
[(rately\),)-201.6(there)-200.4(was)-198.5(no)-202.2(signicant)-198.9(difference)-200.2(in)-202.9(the)-199.8(percentage)-198.5(of)]TJ
T*
[(women)-283.5(using)-285.9(aspirin)-278.9(for)-282.2(secondary)-286.2(prevention.)]TJ
/F10 1 Tf
0 -2.447 TD
[(Statistical)-342.4(analysis)]TJ
/F6 1 Tf
1.1128 -1.8336 TD
[(All)-324.6(variables)-323(were)-324.6(summarized)-326.4(for)-326.4(the)-326.2(two)-321(groups)-328.1(\(those)]TJ
-1.1128 -1.2203 TD
[(taking)-319.2(aspirin)-316.8(and)-315.7(those)-317.7(not)-316.5(taking)-319.2(aspirin\))-317.3(using)-311.2(frequency)]TJ
T*
[(\(percent\).)-299.7(There)-291.4(were)-286.7(two)-289.4(subgroup)-295.9(analyses.)-287.7(Women)-293.5(in)-285.1(the)]TJ
0 -1.2267 TD
[(primary)-488.3(prevention)-490.4(group)-491.1(were)-482.7(analyzed)-487(separately)-491.1(from)]TJ
0 -1.2203 TD
[(those)-418.8(in)-411.6(the)-408.4(secondary)-412.6(prevention)-414.5(group.)-411.9(Multivariable)-417.9(lo-)]TJ
T*
[(gistic)-341.3(regression)-340.4(models)-336.9(estimated)-340.8(odds)-338.9(ratios)-343.4(\(OR\))-337(of)-338.4(com-)]TJ
0 -1.2266 TD
[(plying)-665.6(with)-660.3(guidelines)-662.5(on)-663.7(the)-661.3(use)-666.5(of)-660.8(aspirin)-658.3(and)-663.5(95%)]TJ
0 -1.2203 TD
[(condence)-418.6(intervals)-411.4(\(CI\))-407.9(for)-408.6(the)-414.7(primary)-406.1(prevention)-414.5(group)]TJ
T*
[(and)-448.5(the)-440(secondary)-450.6(prevention)-446.1(group.)-443.5(A)-444(stepwise)-445.7(selection)]TJ
0 -1.2266 TD
[(method)-405.4(was)-400.8(used)-403.9(to)-401.6(establish)-403.1(the)-402.1(nal)-401.5(reduced)-399.2(logistic)-404.6(re-)]TJ
0 -1.2203 TD
[(gression)-422(model.)-414.4(The)-417.3(variables)-417.8(remained)-418.5(in)-411.6(the)-421.1(nal)-414.1(model)]TJ
T*
[(only)-203.8(if)-200(their)]TJ
/F11 1 Tf
5.1848 0 TD
(p)Tj
/F6 1 Tf
.6955 0 TD
[(value)-207.4(was)]TJ
/F9 1 Tf
4.7232 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(0.05.)-200.4(Possible)-201.5(interactions)-201.6(were)-204.5(also)]TJ
-11.3243 -1.2203 TD
[(considered)-453.1(in)-443.2(the)-446.4(model.)-452.3(The)-442.6(OR,)-446.5(95%)-443.3(CI,)-447.8(and)-442.2(parameter)]TJ
0 -1.2266 TD
[(estimates)-187.3(were)-185.5(reported.)-188.8(Goodness)-183.9(of)-186.6(t)-180.5(was)-185.8(checked)-186.2(with)-179.7(the)]TJ
0 -1.2203 TD
[(Hosmer-Lemeshow)-201.9(test.)-201.1(Aspirin)-192.3(use)-198.6(rate)-196.6(over)-193.8(each)-198.1(year)-194.2(of)-192.9(the)]TJ
T*
[(study)-187.6(by)-185.9(prevention)-193.2(group)-187.6(was)-185.8(calculated,)-189.3(and)-189.3(annual)-187.7(aspirin)]TJ
0 -1.2267 TD
[(trend)-696.7(was)-691.7(tested)-687.9(for)-693.1(each)-691.3(prevention)-692.7(group)-693.5(using)-690.6(the)]TJ
/F4 1 Tf
-27.9978 77.2217 TD
(2)Tj
47.3333 0 TD
[(RIVERA)-336.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
59 0 obj
<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/XObject<>/Font<>>>/Thumb 64 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
65 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>/Font<>>>
endobj
60 0 obj
<>stream
/GS1 gs
BT
/F6 1 Tf
8.9663 0 0 8.9663 59.7543 416.6361 Tm
0 0 0 rg
0 Tc
0 Tw
[(Cochran-Armitage)-491.4(test.)-491.9(All)-482.7(tests)-490.3(of)-483.8(signicance)-488.4(were)-482.7(con-)]TJ
0 -1.2203 TD
[(ducted)-190.4(at)-189.7(an)-186.3(alpha)-190.7(level)-191(of)-186.6(0.05.)-187.7(SAS)-188(version)-189.4(9.2)-185.3(\(SAS)-194.8(Institute,)]TJ
0 -1.2266 TD
[(Cary,)-285.9(NC\))-278.8(was)-280.7(used)-283.8(for)-282.1(data)-280.7(analysis.)]TJ
/F4 1 Tf
0 -2.4406 TD
(Results)Tj
/F10 1 Tf
0 -1.8336 TD
[(Prevalence)-334.3(of)-336.7(aspirin)-331.3(use)]TJ
/F6 1 Tf
1.1128 -1.8336 TD
[(From)-429.1(the)-433.7(participating)-432.1(centers,)-431.5(29,701)-430.4(women)-428.9(met)-427.9(eligi-)]TJ
-1.1128 -1.2203 TD
[(bility)-374(criteria)-368(for)-370.7(aspirin)-367.4(use;)-372.2(13,593)-367.2(women)-365.7(met)-371(criteria)-368(for)]TJ
0 -1.2266 TD
[(aspirin)-228.3(use)-223.9(for)-231.6(primary)-222.8(prevention)-231.1(of)-224.5(CVD)-225.7(events,)-223.6(and)-227.2(16,108)]TJ
0 -1.2203 TD
[(met)-295.1(criteria)-292.2(for)-294.8(aspirin)-291.5(use)-293.4(for)-294.8(secondary)-292.5(prevention)-300.7(of)-287.8(CVD)]TJ
T*
[(events.)-286.8(Characteristics)-291.3(of)-281.4(the)-282(women)-283.5(in)-285.1(the)-282(primary)-286(and)-284.1(sec-)]TJ
0 -1.2266 TD
[(ondary)-329.9(prevention)-332.3(groups)-328.1(are)-328.9(summarized)-326.4(in)-329.4(Table)-326.5(2.)-324.9(Only)]TJ
0 -1.2203 TD
[(41%)-304.1(of)-306.7(women)-308.8(who)-305(met)-301.4(criteria)-311.1(for)-301.1(primary)-305(prevention)-313.3(and)]TJ
T*
[(48%)-443.3(of)-439.5(women)-435.2(who)-444.1(met)-434.2(criteria)-443.9(for)-440.2(secondary)-444.2(prevention)]TJ
T*
[(reported)-552.6(taking)-546.9(aspirin.)-547.4(Among)-553.3(the)-547.5(women)-549(in)-544.4(the)-547.5(latter)]TJ
0 -1.2266 TD
[(group,)-298.1(44%)-297.8(of)-300.4(those)]TJ
/F9 1 Tf
9.2884 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(65)-296.2(years)-296.7(of)-300.4(age)-294.7(and)-296.8(63%)-297.8(of)-300.4(those)]TJ
/F9 1 Tf
14.941 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
(65)Tj
-25.671 -1.2203 TD
[(years)-277.7(of)-281.5(age)-275.7(reported)-280.7(they)-280.1(were)-280.3(taking)-275(aspirin.)-281.8(Additionally,)]TJ
28.0042 20.7771 TD
[(66%)-285.2(of)-287.8(those)-292.4(in)-285.1(the)-288.3(secondary)-292.5(prevention)-288(group)-288.8(were)-286.6(taking)]TJ
0 -1.2203 TD
[(aspirin)-506.5(when)-514.1(diabetes)-505.2(was)-508.3(excluded)-511.6(from)-507.3(criteria)-513.5(for)-503.4(the)]TJ
0 -1.2266 TD
[(secondary)-216.6(prevention)-224.8(group.)-215.9(Table)-219(2)-214.5(also)-222.1(summarizes)-217.3(aspirin)]TJ
0 -1.2203 TD
[(use)-280.8(by)-280.7(the)-282(type)-284.4(of)-281.5(CVD,)-285.5(risk)-281.8(factors)-282.7(for)-282.2(CVD,)-279.2(type)-284.3(of)-281.5(health-)]TJ
T*
[(care)-277.6(provider,)-287.5(and)-277.8(self-reported)-286.4(physical)-281.9(activity.)]TJ
/F10 1 Tf
0 -2.8011 TD
[(Predictors)-331.1(of)-336.7(aspirin)-331.3(use:)-334.4(primary)-333.7(prevention)]TJ
/F6 1 Tf
1.1128 -1.8336 TD
[(The)-354(nal)-357.2(reduced)-354.9(multivariable)-359.7(logistic)-360.3(regression)-359.4(model)]TJ
-1.1128 -1.2203 TD
[(for)-313.8(the)-319.9(primary)-317.6(prevention)-319.6(group)-320.4(is)-314.7(summarized)-313.8(in)-316.7(Table)-320.2(3.)]TJ
0 -1.2266 TD
[(Variables)-186(that)-180.9(were)-185.5(associated)-187.7(with)-186.1(aspirin)-184.1(use)-185.9(were)-185.5(ethnicity,)]TJ
0 -1.2203 TD
(\()Tj
/F11 1 Tf
.4869 0 TD
(p)Tj
/F9 1 Tf
.6702 0 TD
(<)Tj
/F6 1 Tf
.7145 0 TD
[(0.0001\),)-282.1(a)-284(smoking)-289.3(status)-282.6(\()]TJ
/F11 1 Tf
11.8112 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
[(0.0275\),)-282.1(having)-286.9(a)-277.7(PCP)-287.4(or)-281.7(a)]TJ
-15.0675 -1.2203 TD
[(cardiologist)-625.5(or)-616.8(both)-624.4(\()]TJ
/F11 1 Tf
10.4075 0 TD
(p)Tj
/F9 1 Tf
.6702 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(0.0001\),)-617.2(use)-622.2(of)-622.9(antihypertensive)]TJ
-11.7986 -1.2203 TD
[(medications)-222.9(\()]TJ
/F11 1 Tf
6.0068 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(0.0001\),)-218.8(a)-220.8(family)-217.7(history)-218.9(of)-218.2(CVD)-219.4(\()]TJ
/F11 1 Tf
14.568 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
(0.0001\),)Tj
-23.3442 -1.2266 TD
[(and)-518.1(a)-524.3(family)-521.2(history)-528.8(of)-521.7(hypercholesterolemia)-527.3(\()]TJ
/F11 1 Tf
21.9595 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
(0.0001\).)Tj
-23.3442 -1.2203 TD
[(African)-368.7(Americans)-367(\()]TJ
/F11 1 Tf
9.1935 0 TD
(p)Tj
/F9 1 Tf
.6702 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(0.0001\))-361.4(were)-368.9(less)-366.5(likely)-367.1(than)-367.2(Cauca-)]TJ
-10.5846 -1.2203 TD
[(sians)-337.9(to)-344.7(take)-339.4(aspirin.)-338.7(Current)-348.1(smokers)-336.8(\()]TJ
/F11 1 Tf
17.7927 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
[(0.0216\))-336.1(were)-343.6(less)]TJ
-19.1774 -1.2266 TD
[(likely)-455.6(to)-464.8(take)-459.5(aspirin)-462.3(than)-462(those)-456.8(who)-463(reported)-464(they)-463.4(never)]TJ
0 -1.2203 TD
[(smoked.)-201.6(Those)-200.1(with)-205(a)-195.5(family)-205(history)-200(of)-199.3(CVD)-200.4(\()]TJ
/F11 1 Tf
19.8539 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
[(0.0001\))-197(were)]TJ
-21.2387 -1.2203 TD
[(more)-190.6(likely)-190.1(to)-186.6(take)-194(aspirin)-190.4(than)-190.1(those)-191.2(with)-192.4(no)-189.5(family)-192.4(history)-193.6(of)]TJ
0 -1.2267 TD
[(CVD.)-418.3(Those)-427.7(with)-420(a)-416.8(family)-426.3(history)-421.3(of)-420.6(hypercholesterolemia)]TJ
0 -1.2203 TD
(\()Tj
/F11 1 Tf
.4869 0 TD
(p)Tj
/F9 1 Tf
.6702 0 TD
(<)Tj
/F6 1 Tf
.7145 0 TD
[(0.0001\))-317.1(were)-318.3(more)-317.1(likely)-316.5(to)-313.1(take)-320.4(aspirin)-316.8(than)-316.6(those)-317.7(with)]TJ
-1.8716 -1.2203 TD
[(no)-278(family)-280.9(history)-282.2(of)-281.5(hypercholesterolemia.)]TJ
1.1128 -1.2266 TD
[(In)-821.2(the)-825.7(multivariable)-821.3(model,)-825.3(an)-824.9(interaction)-826.3(between)]TJ
-1.1128 -1.2203 TD
[(healthcare)-540.7(provider)-537.5(and)-537(antihypertensive)-544.4(medication)-544.1(was)]TJ
T*
[(found)-599(to)-597.6(be)-592.4(signicant)-603.5(\()]TJ
/F11 1 Tf
11.9313 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(<)Tj
/F6 1 Tf
.7208 0 TD
[(0.0001\).)-598.2(Goodness)-594.9(of)-597.6(t)-597.8(test)]TJ
-13.3161 -1.2203 TD
[(\(Hosmer-Lemeshow)-537.4(test)-533.3(statistic)]TJ
/F9 1 Tf
14.9916 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
(4.38,)Tj
/F11 1 Tf
2.5292 0 TD
(p)Tj
/F9 1 Tf
.6639 0 TD
(=)Tj
/F6 1 Tf
.7208 0 TD
[(0.8209\))-532.1(showed)]TJ
-19.6263 -1.2266 TD
[(adequate)-204.1(model)-209.1(calibration.)-206.9(Women)-205(who)-203.8(had)-208.2(both)-207.1(a)-201.8(PCP)-205.2(and)]TJ
0 -1.2203 TD
[(a)-195.5(cardiologist)-201.9(or)-193.2(at)-202.3(least)-194.4(one)-202.1(\(a)-196(PCP)-198.9(or)-193.2(cardiologist\))-202.4(were)-198.1(more)]TJ
T*
[(likely)-329.2(to)-325.7(take)-326.8(aspirin)-329.5(than)-329.2(those)-330.3(who)-330.2(did)-325.7(not)-329.1(have)-326(a)-328.3(PCP)-331.7(or)]TJ
0 -1.2266 TD
[(cardiologist.)-489.3(Women)-489.5(who)-488.3(had)-486.4(hypertension)-498.7(or)-484(who)-488.3(were)]TJ
0 -1.2203 TD
[(taking)-243.4(antihypertensive)-247.2(medications)-248.2(were)-242.4(more)-241.2(likely)-246.9(to)-243.5(take)]TJ
T*
[(aspirin)-405.4(than)-405.1(those)-406.2(who)-406.1(did)-401.6(not)-405(take)-402.6(antihypertensives.)-415.8(Be-)]TJ
0 -1.2267 TD
[(cause)-519.8(of)-521.7(the)-522.2(interaction)-529.1(between)-521.8(healthcare)-521.7(provider)-524.9(and)]TJ
ET
59.811 178.753 239.131 .22676 re
f
59.811 57.146 239.131 .22678 re
f
BT
/F8 1 Tf
8.9663 0 0 8.9663 85.2094 204.3212 Tm
(Table)Tj
/F6 1 Tf
3.0666 0 TD
(1.)Tj
/F8 1 Tf
1.2456 0 TD
[(American)-336.3(Heart)-333.2(Association)]TJ
/F6 1 Tf
14.6881 0 TD
(2007)Tj
/F8 1 Tf
-20.1954 -1.1065 TD
[(Guidelines)-335.1(for)-334.5(Aspirin)-333.5(Use)-339.6(for)-334.5(Cardiovascular)]TJ
4.3628 -1.1128 TD
[(Disease)-334.5(Prevention)-336.4(in)-335.1(Women)]TJ
/F6 1 Tf
-6.0004 -2.0423 TD
[(Primary)-336.6(prevention)-338.6(\(other)-336.5(at-risk)-332.9(or)-338.6(healthy)-337.1(women\))]TJ
.999 -1.1128 TD
[(Consider)-337.2(aspirin)-335.8(therapy)-338.5(in)-335.7(women)]TJ
/F9 1 Tf
16.3827 0 TD
()Tj
/F6 1 Tf
.7208 0 TD
[(65)-334.1(years)-334.6(if)-332.8(blood)]TJ
-18.1025 -1.1128 TD
[(pressure)-335.3(is)-333.6(well)-337.4(controlled)-335.5(and)-334.7(benet)-339.9(for)-332.7(ischemic)-336.6(stroke)]TJ
T*
[(and)-334.7(myocardial)-336.3(infarction)-333.2(prevention)-344.9(is)-333.6(likely)-329.2(to)-338.4(outweigh)]TJ
0 -1.1065 TD
[(the)-300.9(risk)-300.8(of)-300.4(gastrointestinal)-306.4(bleeding)-306.6(and)-296.8(hemorrhagic)-306(stroke.)]TJ
0 -1.4479 TD
[(Secondary)-333.9(prevention)-344.9(\(high)-331.3(risk\))]TJ
.999 -1.1065 TD
[(Aspirin)-337.7(therapy)-338.5(should)-331.5(be)-339.4(used)-334.4(in)-329.4(high-risk)-341.3(women)]TJ
-.999 -1.1128 TD
[(\(established)-317.9(coronary)-317(heart)-313.8(disease,)-321.2(cerebrovascular)-317.1(disease,)]TJ
T*
[(peripheral)-311(arterial)-311.4(disease,)-308.6(abdominal)-314.4(aortic)-309.8(aneurysm,)-308.2(end-)]TJ
T*
[(stage)-296.5(or)-294.3(chronic)-296.9(renal)-297.9(disease,)-295.9(diabetes)-296.6(mellitus,)-292.3(and)-296.8(10-year)]TJ
0 -1.1065 TD
[(Framingham)-336.5(risk)]TJ
/F9 1 Tf
7.8025 0 TD
(>)Tj
/F6 1 Tf
.7145 0 TD
[(20%\))-336.2(unless)-339.6(contraindicated.)]TJ
ET
q
301.377 0 0 282.274 59.754 451.729 cm
/Im1 Do
Q
BT
/F7 1 Tf
8.9663 0 0 8.9663 373.6629 594.0849 Tm
[(FIG.)-532.8(1.)]TJ
/F6 1 Tf
4.2933 0 TD
[(Flow)-530.8(chart)-534.5(of)-534.4(study)-535.4(participants.)]TJ
-4.2933 -1.1065 TD
[(ASA,)-333(acetylsalicylic)-341.2(acid)-327.8(\(aspirin\).)]TJ
/F4 1 Tf
-35.01 18.4629 TD
[(UNDERUSE)-342.9(OF)-331.2(ASPIRIN)-333.8(IN)-335.1(PREVENTION)-341.1(OF)-331.2(CVD)-30081.6(3)]TJ
ET
endstream
endobj
61 0 obj
<>stream
Adobe d C
Mt
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳf͛6lٳf͛6lٳf͛6lٳf͐O?:kz )$3y[*KqS[Ky2ڄiTg.{˰Z%!)1T B ћL 7֛ S. Fo3O7] B~jj_P07Da ֙ S. Fc 8ћK?y: 4f z?twh BћL 7֙ S. Fo3_7] /ZoNn ti+kFu-E}X@J}omS[:;xV
Z9z[s pjMsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛92 CyD
=m=U%tٳf-__/XUMǘp>C |.91Oog&L-3Z>ƭRT7-r,>`65WK!\F,b^U_1\Cu4FA"dTfۉ/˿O4j6u7זLBX'lqmoWWW_41/oq SՍ)79fEE3Z 91|qKtG;M:lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg7 yZgΑ(_@Mqzktҷ]ҳ֜U&,OEҙf ~i~tW7BGt&V
DPiJ`9~Z~WkZ0}ۍ3kB5X+o巔1XSӴ[G2*jTw~Sկo:yub5s$:x*ȍG 03mR]sIk4n6P1fҡv_巚4|t^8mQX'~7'; 5ƼsA|vlc ֛ u,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfo O=q#6b*y; )("yR8Xy3z~m~hzƬ^-?@CusgSܒC<AۈSZgiil!Z:"}g9.h?o7^wש#KnьLG#"zaMy7nu-[O tk5dRIW2?'